[go: up one dir, main page]

HUE035618T2 - Ellenanyag-kiszerelés és terápiás rendek - Google Patents

Ellenanyag-kiszerelés és terápiás rendek Download PDF

Info

Publication number
HUE035618T2
HUE035618T2 HUE11705713A HUE11705713A HUE035618T2 HU E035618 T2 HUE035618 T2 HU E035618T2 HU E11705713 A HUE11705713 A HU E11705713A HU E11705713 A HUE11705713 A HU E11705713A HU E035618 T2 HUE035618 T2 HU E035618T2
Authority
HU
Hungary
Prior art keywords
administered
psoriasis
dose
patients
administration
Prior art date
Application number
HUE11705713A
Other languages
English (en)
Inventor
Dingjiang Liu
Holly Zhuohong Huang
David Andrew Martin
Christopher Boyd Russell
David H Salinger
Scott Walter Baumgartner
Christopher J Endres
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE035618(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of HUE035618T2 publication Critical patent/HUE035618T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)

Claims (9)

  1. Szabadakéi igénypontok t. gyógyászati kiszerelés, amely giutamátsav pnffer ás ellenanyag vizes oldatát -tartalmazza, az ellenanyag tartalmaz :SEQ 1B N0;3 szerinti szekvenciát tartalmazd nehézlánc· variábilis dómén szekvenciái és SEQ H> NO:4-szerinti szekvenciát tartalmazó könnyóláns variábilis dómén szekvnnn;át, ahol az ellenanyag specifikusan köti· a humán I1,-1 7 receptor A-t, és ahol: a) a kiszerelés glntaminsavat tartalmaz S-3Ö mM « 0,2 mM- koncentrációban; >>) a kiszerelés pli-js 4,5-5,2 2 0,2; ei a kiszerelés továbbá tartalmaz 2-4% prolim (rvAA és 0,005-0,0221 (sv/v} pollsznt'bát 28-at; d) az-ellenanyag koncentrációja 100-150 mg/mt
  2. 2. Az ;. igénypont szérmti gyógyászati klsZédOés, ahol az ellenanyag SÜQ ií) lónkl szerinti szekvenciát Uiv'..n'3ze nvtuAnr '.<1 tvnv át o\ S; rj 0* be' s.oíut. αΆα κ 't tanaim» '' kom".»d.m<. tc»\ Hts > 1>(>ÍA 'tv Μ \ ,2\μ P a,' tu '\i a M't >t Hinne » ·, \! t c\ ,y IP Nö:2 szerinti szekvenciát tartalmazó könnyű lánc szekvenciát tartalmaz.
    2, Az 1. vágy 2. igénypont szerinti gyógyászát! kiszerelés, amelynek továbbá az -cmtmiarltása 250 - 400 mÖsm/L,
  3. 4, Gyógyászati tartály, amely edényt és az I--3. igénypontok bármelyike szerinti gyógyászat; kiszerelést tártaiméi ahol az edény fiola, öveg, előre megtöltőt! leeskenöd, vagy előre megtöltött .autoinjéktorös fecskendő.
  4. 5, Készlet, amely egy vagy több 4. igényperé szerinti: gyógyászét; tartályt és azok a-lkaltmtzfoárá szolgáló utasításokat tartalmaz. ő, Az 1-2, igénypernek bármelyike szerinti gyógyásza;! kiszerelés, pszoriázis humán páciensben való kezelésében történő alkalmazásra, ahol az ellenanyag dózisa 70, 140, 210 vagy 280 mg.
  5. 7, A Ó, igénypont szerinti gyógyászati kiBZértdés alkalmazásra, aboi a páelebsoek az eiionanyág 70 - 280 mg dózisíi van bead va minden bélen, mindcsi második héten ós/ vagy havoóm, 8, A 7. igénypont szerinti gyógyászai! kiszerelés alkalmazásra, ahol az ellenanyag 140 mg dózisa van beadva a páciensnek, ha a tömege kisebb nnnt vagy megközelítőleg egyenlő 100 kg, és ahol az ellenanyag 210 mg dózisa var; beadva a páciensnek, ha a tömege nagyobb mim 1.00 kg.
  6. 9, A ó< igénypímmk bármelyike szerinti gyógyászati kiszerelés alkalmazásra, ahol a pszoriázis a kővetkezők állal alkotott csoportból van kdval&amp;sztva; a) piakkos pszori ází s: b'; líőzepes-sályóS piákkor pszoriázis; m krónikus közepes-súlyos okikkor pszoriázis és a páciensek szisztémás íe-rúpiás vagy íbtosorápiás jelöltek; és éh krónikás közepes-súlyok plákkos pszöriázis és ahol a páelenséfc stcm reagáltak vagy eltesgavalltsk vagy iPtoleráásák más szisztémás terápiákra., beleértve elklospörltp mútúíréxá?. és pszoeatés-s plrssz 0hrrnhot;, ,ι- Λ *ototempni tO V *' , '\!' >i U'\ ' \ l i. \ ' ' ' S S l <>..', k < < S S , ls l tartalmaz körülbelül 140 svig/rot ellenanyagot, kiszerelve 16 s·. 0,2 «Μ gbáatnmsavval, 3 £ 6,2% <w/v.s L-proiitmai, 0,01 *. 0,002% (w/v) poilszorbáí 26-al, pH 4,8 «· 0,2. H, \ b-10 igetívpontok b;aun-h ske c/cnnti gvegvu.vmi kiszerelés ,ilkalmai· asm, almi a gyógyászát! kiszerelés sazsbkutáiv, intrttd«smá.!ísan, iPttmwszknlárisa.Tt és/vagy inbaváriásan. wt.feesdva.
  7. 12, Gyógyászati kiszerelés, ..amely -'körülbelül 1:06-1.50· mg/snl eiiananyagot tartalmaz, a következőkkel kiszerelve: s s gtístasssIm.av 10 -svM kíssvcesvbáíássbatS; sí) pH 4.8 ,ϊ. 0,2; s is) 3% ptplbv (wp·} és 0,0i % (vv/v) poilszorbáí: 00; akpl az ellenanyag a. köveíkszók állei aiktstotí: esöporsOpf vpp-kiválasztva: s> Μ\,> 6> V* ' "üí! ene',n 5,οι<Οη·ζ,'ό ιηΊ'η,Ί,',η', \(in,'bii>s ,t,>ín<s> s.ekvenema es $1 *2 iP NO:4 szerinti szekvenciát tartalmazó böntsyáiáíic· variábilis dómén szekvenciát iartalmazó ellenanyag, apui az eilemsoyog spceifiktíSáís köti á hüínán IL·· I 7 receptor A·a; és h) a JsBQ ffit-NCM szerisro székvssseiát ívataltriazó. nehéZlápc szekvesvclaí: éc bBQ iD MG:2 szeriísti: V, SU(I Sí ' ' ' s "i ' ! < ! , ',í K 1 í ' ' < < V ií ‘KJ', k > sk,f\ ' í s < 1 IP \ó ' s ' * S szekvenciát tartalmazó iseisczbíse. szekvenciát és 5KQ ID NO:2. szerinti szekvenciát tartalmazó kópnyólápe séékvcsicsái tartalísiazó eiics'anyag, psz-órláZssós hs'íkrilisz hgtóán pééieoshso vsdó kezelési eijásásáOssís történő alkalsv-azásra, ahol az ellenanyag dózisa 76, 140, 210 vagy 280 mg.
  8. 13, Gyógyászati kiszerelés, amely kOfülbolúl 15)0-ISO nvg/spl áöópensngví tttmitóéks a következőkkel: kiszerelve; í) gkiOmimsav 10 mM kosieePPácsóbstt; ;l) pH 4,8 *0,2; Ht) 3% pról:ia:(w/y) és 0,01% (w/v) pollszorbái 20; Ιό v,. \xesc, < ?,i> a I előtt, »env ,be^ 'Γ c v 4 m a) r>b'O IP N'-‘szerűin 5,?emeae>as mrtóima.'ö neite’bnc satfáNOs dómén székeenemt cs Si <) 10 Nt't 4 veuob szekvenciát tartalmazó kbsmvtslanc vurhbshs d<w szekvenciái tartalmazó ctlenanyag, ahol az ellesi anyag specifikusan köti a humán 11..-17 receptor A-t; és bj &amp; SEQ ID MOH szerltstl szekvenciát tartalmazó svebéziánc szekyetielái ék SEí) ID bÍG:2 ezéritsts szekvenciát tartaima'O kónnvuktm srekvenet,r, v,te< mos megadásképpen ΌΊ) IP \<> 1' s/enno s s ή v ' n< v c ' ri s, w,s\ i , s ,; ,P \,i ' , ,ss > < ,t„iut i< ttt' oc körmyűláne szekvenciát tartalmazó ellenanyag, asztma humán páciensben való kezelési eljárásábsm törléssö: alkalmazásra, ahol az ellesuiayag dózisa 70, 140, 210 vagy 280 mg. kHzvrelés, adéiy kbrtliOHat iOddSO mg/ítii «ita$8ya$»t Wtato, P Mövd.bAk«l '·:«·;>'<{<·;ν·ν: s! glwsoíodtv iö raM kiérééísírpsióbss.; a) pH éd z 0/7: íü) 3% próba (w.A?) és 0,042ó (vdv) pdlszaraz· 2ik ahöi az eiteusyag a /kövétteók isid dkaióö ésapartdól vsa kivélssziva; a) bkQ 0) NON szsrdb szskvváaiéi iériaiisazé héhéztoe vsííáWU siataóa szekvaasiái és OOP) IF> iH0;4 szar lati szdíVétídsá tpHadáázó kóaayrOaar. vsrtáfeiÜs dósod! sZékVéswsii tSiidsOázd slléhányágs ab<0 rsz rdies^aoyag apadOkossá köti a koosaa 4,0 7 soségtíO A-s: ós A) s SBQ il> HÖH szériát; szekveadát driaOapzö oeháxlátK? szakosodét és OisQ ID NO:2 szeriob szakozódét tartsisisző köaoyálaae szekvaoaiét, vagy atés aseyatdóstíépgso SPQ Ο) NOH2 szerűéi szvkvaoiééi iéttsbmszó stehéztéoc szekve setéi és 2BQ 02 Hőd óéeríott szakosadéi tana boazó kósaosiéae szekvvooiái iértalrstéza siiesaayttgs spaiidyiitss áókylöpöéiíés bitűtéo pádaosbso való kezdési vdaHisAbss brrteaó atkaiiöazésrs, aböl pz PlivOPOOsA ÓAzIsa 70< Í4Ó, 7 > 0 vagy 240 rag. 1 ó, Gyógyászati kiszerelés, as-tely karSiOsOti ÍÖÖ4S0 rágást dleooayayai iMtdaw, a kOvsikezókkei kHzvívioé: i! giríiaíOtaspv : 0 otlM kravoré; Práabrav ;0 pH éd s g.g; im Ά \v >υν \ < a 0' \ v< ’ > !s^aH'(a \ ahd pz dlesasyxg a krtvstkezók akid rstkvastt esv;x>t'á;»l oáó kiválasztva; ó) ggQ 00 Hőd szvristi spakvpasiéi tériPisspzó pspéztásie vta-iébiiis dpoéo szakóvodát ésdbikQ iH NÖ;4 szarioti szekyvoíéél tartakbázP késsyüíáss vaOáhsOs dössép szakvasviát tpririboazó sOasssys^ shd az iéldksAysg sped iikasaa kiéi a kostáé Π,-t7 dáspíót A-g és k) a SBQ lő Néki szer tót i szekveaesát ksridszsézb rtehéziéitc szsksarodái és OEQ lü :HG;7 szartad szék svadét tsripistáZd kartayéiéov szekvedeiék vagy órás rftegóidéékvypvz Sl/ő 1I> NO: 17 szeried szekovoviét iarspiaípzé asóéziááé saekyvtsóiai és SléQ Og Hőd szerda szekovrrdét iarizdtaaó köoayritasr: szekvvrtdát téí'iáhéézd vibrtéóoég, seivrosis sadápiez lisraés pédeasbea oísíó kezdési vbéiésébpe tPrsésO zlkpisdéPái's, ríbol az ebésasosg épzípa 70. 1 -07, 710 vagy 200 dg. 16. A |2-, · s. igéaypisasik béríaelytkv szériáti gyógyászati kiszsréiés add ess zásra. ahöi p gyógyászati kiszerelés továfebé iartaisipz ksíiiibdd i 40 rágást dieatiayagid, és éboi a gyógyszer viszkezkása 5 - 7 <s 24 áli-ea.
  9. 17, A Ι2Ί Ρ. igeeypastsd bétsaelyike szérlati gyógyászati kiszsrdés alkélsatzástig ahd e gyógyászati kiszerelés szoPkatáé, iátraéettoáiiséiz iréréétoszktilásásstt ésNágy isiéévéPéspá ess bvabop.
HUE11705713A 2010-01-15 2011-01-12 Ellenanyag-kiszerelés és terápiás rendek HUE035618T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10

Publications (1)

Publication Number Publication Date
HUE035618T2 true HUE035618T2 (hu) 2018-05-28

Family

ID=43858045

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11705713A HUE035618T2 (hu) 2010-01-15 2011-01-12 Ellenanyag-kiszerelés és terápiás rendek
HUE17195530A HUE046670T2 (hu) 2010-01-15 2011-01-12 Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE17195530A HUE046670T2 (hu) 2010-01-15 2011-01-12 Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére

Country Status (38)

Country Link
US (5) US8883151B2 (hu)
EP (3) EP2523688B1 (hu)
JP (2) JP5743234B2 (hu)
KR (1) KR101766936B1 (hu)
CN (1) CN102821787B (hu)
AR (1) AR079903A1 (hu)
AU (3) AU2011205402B2 (hu)
BR (1) BR112012017150B1 (hu)
CA (1) CA2787128C (hu)
CL (1) CL2012001966A1 (hu)
CO (1) CO6640206A2 (hu)
CR (1) CR20120419A (hu)
CY (2) CY1119852T1 (hu)
DK (2) DK3295957T3 (hu)
EA (2) EA031209B9 (hu)
ES (2) ES2652637T3 (hu)
HR (1) HRP20171939T1 (hu)
HU (2) HUE035618T2 (hu)
IL (1) IL220602B (hu)
IN (1) IN2012DN06720A (hu)
LT (2) LT2523688T (hu)
MA (1) MA33989B1 (hu)
MX (1) MX349856B (hu)
MY (1) MY182680A (hu)
NO (1) NO2523688T3 (hu)
NZ (1) NZ601125A (hu)
PE (1) PE20121691A1 (hu)
PH (1) PH12012501364A1 (hu)
PL (2) PL3295957T3 (hu)
PT (2) PT2523688T (hu)
RS (2) RS56781B1 (hu)
SG (2) SG10201604093XA (hu)
SI (2) SI3295957T1 (hu)
TN (1) TN2012000335A1 (hu)
TW (1) TWI554282B (hu)
UA (1) UA112288C2 (hu)
WO (1) WO2011088120A1 (hu)
ZA (1) ZA201205167B (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
BR112012017150B1 (pt) 2010-01-15 2022-03-03 Kirin-Amgen Inc Formulação farmacêutica, recipiente farmacêutico, e kit
ES2716088T3 (es) * 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
CA2791951C (en) 2010-05-20 2019-05-14 Ablynx Nv Biological materials related to her3
CA2814780C (en) * 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
CA2832556A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3492099A1 (en) * 2011-11-23 2019-06-05 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
EP3156073A1 (en) * 2012-03-07 2017-04-19 Eli Lilly and Company Il-17 antibody formulation
AU2013262083A1 (en) 2012-05-14 2014-11-06 Novo Nordisk A/S Stabilised protein solutions
AP2015008801A0 (en) 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
EA201591581A1 (ru) 2013-03-15 2016-01-29 Амген Инк. Способы лечения псориаза при помощи анти-il-23 антитела
ES2760002T3 (es) * 2014-03-31 2020-05-12 Amgen K A Inc Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
KR102427097B1 (ko) * 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법
WO2016039319A1 (ja) * 2014-09-10 2016-03-17 日油株式会社 蛋白質吸着抑制剤及び蛋白質吸着抑制方法
DK3763384T3 (da) 2014-12-03 2024-09-23 Csl Behring Ag Farmaceuitisk produkt med øget stabilitet, omfattende immunoglobuliner
CA2998349A1 (en) 2015-09-17 2017-03-23 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
CA3002761A1 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
EP3393515A4 (en) 2015-12-22 2019-08-14 Amgen Inc. CCL20 AS A PREDICTOR FOR CLINICAL RESPONSE TO IL23 ANTAGONISTS
CN109073949B (zh) 2016-04-19 2022-01-11 Sage电致变色显示有限公司 包括透明导电氧化物层和汇流条的电致变色装置和其形成方法
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (en) * 2017-07-26 2019-01-26 Michael Giroux Safety anchor and roof vent
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EA202190197A1 (ru) 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
JP2022547678A (ja) 2019-09-11 2022-11-15 ボシュ ヘルス アイルランド リミテッド Ｉｌ－１７ｒａ抗体を用いた非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の治療方法
CN111840217B (zh) * 2020-06-19 2021-04-02 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2023240071A1 (en) * 2022-06-06 2023-12-14 Fusion Pharmaceuticals Inc. Methods of dosing therapeutic agents

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0393438B1 (de) 1989-04-21 2005-02-16 Amgen Inc. TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
DE69017753T3 (de) 1989-05-18 2013-06-20 Yeda Research And Development Co., Ltd. Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
DE69022559T2 (de) 1989-12-13 1996-05-02 Yeda Res & Dev Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
ES2251009T3 (es) 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
WO1992001002A1 (fr) 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
DE69230789T3 (de) 1991-01-18 2007-10-31 Amgen Inc., Thousand Oaks Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
SG47099A1 (en) 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE242322T1 (de) 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
EP0639079B1 (en) 1992-04-30 2000-01-12 Amgen Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
WO1994006476A1 (en) 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
NZ306653A (en) 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
AU727480B2 (en) 1995-07-19 2000-12-14 Genetics Institute, Llc Human CTLA-8 and uses of CTLA-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
ES2326347T3 (es) 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999014240A1 (en) 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
ATE365800T1 (de) 1998-05-15 2007-07-15 Genentech Inc Therapeutische verwendungen von il-17 homologe polypeptide
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
US20020045213A1 (en) 2000-03-16 2002-04-18 Shuqian Jing IL-17 receptor like molecules and uses thereof
AR030554A1 (es) 2000-03-16 2003-08-27 Amgen Inc Moleculas similares a receptores il-17 y usos de las mismas
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO2002058717A2 (en) 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
US20050153880A1 (en) 2002-06-27 2005-07-14 Yukio Goto Methods of treating or preventing ibd with il-18
SI1517921T1 (sl) 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP2007501252A (ja) 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
MXPA06014053A (es) 2004-06-04 2007-07-11 Designer Molecules Inc Poliesteres de radicales libres curables y metodos para uso de los mismos.
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP2008532493A (ja) 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
ES2333260T3 (es) 2005-09-01 2010-02-18 Schering Corporation Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica.
CA2624763A1 (en) 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
SI1942868T2 (sl) 2005-11-01 2023-12-29 Wyeth Llc Raztopina natrijevega klorida za rekonstitucijo zdravil ali razredčenje
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
CN101541833B (zh) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 Il-17受体a抗原结合蛋白质
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
WO2008049070A2 (en) 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
US20080213282A1 (en) * 2006-12-21 2008-09-04 Jaby Jacob Formulations
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN101679497A (zh) 2007-03-26 2010-03-24 津莫吉尼蒂克斯公司 可溶性il-17ra/rc融合蛋白以及相关方法
CA2687720A1 (en) * 2007-06-13 2008-12-24 Amgen Inc. Il-17 heteromeric receptor complex
US20110014676A1 (en) 2007-06-29 2011-01-20 Battelle Memorial Institute Protein stabilization
MX2010001723A (es) 2007-08-17 2010-04-30 Amgen Inc Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes.
KR101240904B1 (ko) 2008-02-21 2013-03-11 키린-암젠 인코포레이티드 Ｉｌ-１７ｒａ-ｉｌ-１７ｒｂ 길항제 및 그의 용도
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
BR112012017150B1 (pt) 2010-01-15 2022-03-03 Kirin-Amgen Inc Formulação farmacêutica, recipiente farmacêutico, e kit
DK2625199T3 (en) 2010-10-08 2018-02-26 Novartis Ag Method of treating psoriasis using IL-17 antagonists
EP2633317A1 (en) 2010-10-25 2013-09-04 Genentech, Inc. Treatment of gastrointestinal inflammation and psoriasis a
CA2832560A1 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
CA2832556A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
ES2760002T3 (es) 2014-03-31 2020-05-12 Amgen K A Inc Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo
KR102427097B1 (ko) 2014-08-26 2022-08-01 암젠 케이-에이, 인크. 항-tnf-알파 항체 요법을 받은 건선 환자의 치료 방법

Also Published As

Publication number Publication date
US10808033B2 (en) 2020-10-20
AU2015202023B2 (en) 2017-05-18
BR112012017150A2 (pt) 2017-10-10
AU2011205402A1 (en) 2012-07-12
TW201129382A (en) 2011-09-01
EP3632466A1 (en) 2020-04-08
CN102821787B (zh) 2015-07-29
JP2013517277A (ja) 2013-05-16
CY1122466T1 (el) 2020-10-14
EA031209B1 (ru) 2018-12-28
JP2015052017A (ja) 2015-03-19
PL3295957T3 (pl) 2020-03-31
SG10201604093XA (en) 2016-07-28
JP5743234B2 (ja) 2015-07-01
EA201290653A1 (ru) 2013-02-28
LT2523688T (lt) 2018-03-12
EA201891433A3 (ru) 2019-02-28
CA2787128C (en) 2019-06-11
NZ601125A (en) 2014-08-29
PL2523688T3 (pl) 2018-04-30
AU2017216579A1 (en) 2017-09-07
ES2652637T3 (es) 2018-02-05
MX349856B (es) 2017-08-16
EP2523688B1 (en) 2017-10-11
PT2523688T (pt) 2018-01-05
BR112012017150B1 (pt) 2022-03-03
AU2011205402B2 (en) 2015-02-05
KR20120118036A (ko) 2012-10-25
US8883151B2 (en) 2014-11-11
WO2011088120A8 (en) 2012-09-13
US20230192873A1 (en) 2023-06-22
EP2523688A1 (en) 2012-11-21
LT3295957T (lt) 2020-01-27
PT3295957T (pt) 2019-11-12
SI2523688T1 (en) 2018-03-30
US20130022621A1 (en) 2013-01-24
NO2523688T3 (hu) 2018-03-10
ES2753216T3 (es) 2020-04-07
WO2011088120A1 (en) 2011-07-21
AR079903A1 (es) 2012-02-29
IN2012DN06720A (hu) 2015-10-23
EA201891433A2 (ru) 2018-11-30
EP3295957B1 (en) 2019-08-07
PE20121691A1 (es) 2012-12-14
US10072085B2 (en) 2018-09-11
TN2012000335A1 (en) 2013-12-12
DK2523688T3 (en) 2017-12-04
US20150017184A1 (en) 2015-01-15
CL2012001966A1 (es) 2013-01-18
US20180346583A1 (en) 2018-12-06
CY1119852T1 (el) 2018-06-27
HUE046670T2 (hu) 2020-03-30
EA031209B9 (ru) 2021-11-19
ZA201205167B (en) 2013-03-27
CO6640206A2 (es) 2013-03-22
RS56781B1 (sr) 2018-04-30
MA33989B1 (fr) 2013-02-01
US11505612B2 (en) 2022-11-22
KR101766936B1 (ko) 2017-08-09
AU2015202023A1 (en) 2015-05-14
US20200399384A1 (en) 2020-12-24
RS59743B1 (sr) 2020-02-28
SG182468A1 (en) 2012-08-30
DK3295957T3 (da) 2019-10-14
WO2011088120A9 (en) 2012-08-09
HRP20171939T1 (hr) 2018-03-23
CR20120419A (es) 2012-11-29
SI3295957T1 (sl) 2020-02-28
IL220602B (en) 2019-03-31
TWI554282B (zh) 2016-10-21
CN102821787A (zh) 2012-12-12
UA112288C2 (uk) 2016-08-25
MX2012008213A (es) 2012-11-06
PH12012501364A1 (en) 2012-10-22
MY182680A (en) 2021-01-29
EP3295957A1 (en) 2018-03-21
CA2787128A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
US20230192873A1 (en) Method of treating diseases using an il-17 receptor antibody formulation
TW201632203A (zh) 用於單株抗體的穩定液體製劑
JP6265970B2 (ja) 安定なＩｇＧ４に基づく結合剤の製剤
AU2014314053B2 (en) Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
AU2013202139A1 (en) Antibody formulation and therapeutic regimens
EA040869B1 (ru) Фармацевтический состав для лечения воспалительных заболеваний